Skip main navigation

Insights & Publications

Pharmaceuticals & Medical Products

Pharma-launches_1536x1536_Thumbnail
article

The secret of successful drug launches

March 2014—About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.more

Editor's choice

Pharma-mergers_1536x1536_Thumbnail
article

Why pharma megamergers work

February 2014—Unlike deals in many industries, big mergers and acquisitions among pharmaceutical companies generally have resulted in positive returns to shareholders.more

FDAapprovals_1536x1152_Thumbnail
article

What’s driving the surge in new-drug approvals?

November 2013—In 2012, new-drug approvals by the US Food and Drug Administration hit a ten-year high. Can the pharmaceutical industry make this trend last?more

HealthCareSupplyChain_1536x1152_Thumbnail
article

Strengthening health care’s supply chain: A five-step plan

September 2013—Dramatically changing the sector’s inefficient supply chain may eliminate the dangers posed by counterfeiting and medication errors.more

  • includes:
    •  
hobi13_frth_Thumbnail
article

How big data can revolutionize pharmaceutical R&D

April 2013—Pharmaceutical R&D suffers from declining success rates and a stagnant pipeline. Big data and the analytics that go with it could be a key element of the cure.more

  • includes:
    •  
reva12_1536x1152_Thumbnail
article

Restoring value to biopharmaceutical R&D

August 2012—After years of seeing value destroyed by R&D excesses, biopharmaceutical companies can gain healthier returns—but only if they recognize several new imperatives.more

inch12_frth_Thumbnail
interview

Innovating in China’s pharma market: An interview with AstraZeneca’s head of R&D in Asia and emerging markets

February 2012—The country may well foster new models of innovation, but success will require a long-term commitment and talent development.more

cabr12_frth_Thumbnail
article

Capturing the Brazilian pharma opportunity

April 2012—Global pharma companies are missing a chance to serve Brazil’s increasingly prosperous and growing middle class.more

heca12_frth_Thumbnail
article

Health care in China: Entering ‘uncharted waters’

November 2012—Multinationals are flocking to take advantage of the opportunities, but long-term success is by no means assured.more

About this content

The material on this page draws on the research and experience of McKinsey consultants and other sources. To learn more about our expertise, please visit the Pharmaceuticals & Medical Products Practice.